@article{ATM25070,
author = {Li Shu and Qianhua Xu and Qingxia Meng and Xue Dai and Yun Zhang and Wei Zhou and Honggang Yi and Jinyong Liu and Chunxiang Wu and Zhen Hou and Yugui Cui and Tin Chiu Li and Jiayin Liu},
title = {Clinical outcomes following long GnRHa ovarian stimulation with highly purified human menopausal gonadotropin plus rFSH or rFSH in patients undergoing in vitro fertilization-embryo transfer: a multi-center randomized controlled trial},
journal = {Annals of Translational Medicine},
volume = {7},
number = {7},
year = {2019},
keywords = {},
abstract = {Background: This clinical trial aimed to compare the clinical efficacy of highly purified human menopausal gonadotropin (HP-HMG) plus recombinant human follicle-stimulating hormone (rFSH) versus rFSH alone on controlled ovarian stimulation (COS) in vitro fertilization-embryo transfer (IVF-ET).
Methods: A total of 610 women underwent long gonadotropin-releasing hormone (GnRH) agonist protocol for IVF treatment. The subjects were randomized into 2 groups: HP-HMG + rFSH group (n=305) and rFSH group (n=305). The main outcome was the progesterone (P) level on the day of HCG injection.
Results: There was no significant difference in terms of the demographic and baseline characters between the two groups. In rFSH group, the P level on the day of HCG trigger were significantly higher than that of HP-HMG+rFSH group (4.3±2.2 vs. 3.8±1.7 nmol/L, P},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/25070}
}